Despite the risks and volatility in the U.S. stock market, there are many bargains emerging – if you know where to look. In this issue, we’re providing updates for six stocks in the portfolio that each trade at highly attractive valuations – and are being overlooked by Wall Street.
Dear Biotech Frontiers subscribers, I’m writing to you with two sell recommendations from the Biotech Frontiers portfolio this morning – one driven by good news, the other by bad. Let’s start with the good news. Last July, we recommended TG Therapeutics (Nasdaq: TGTX) with an entry price of $18.79 per share. We suggested that TG
Stocks in the S&P 500 are currently trading at sky-high valuations. With a weakening economy, it’s only a matter of time before share prices fall to levels at which valuation multiples decline to historical averages.
Today we look at the key vulnerability facing the U.S. economy: the end of the wealth effect created from the greatest bull market of the last 50 years, and how it removes a key pillar of strength holding up the U.S. economy.
The top 10% of earners have been driving the economy. But now the data shows that even this segment of society is slowing their spending, causing key sectors of the economy to signal trouble ahead.
Mutual fund cash levels have historically been one of the best contrarian indicators of where the market is headed… one that’s still well worth tracking today. And right now, asset managers are holding their lowest levels of cash in history – meaning they think the market is headed higher.
Today we’re turning over the entire issue to readers. Over the last few weeks, Porter has written about a few topics that have generated more feedback than usual – on distressed investing, Trump’s economic policies, and more… Plus, some fishing photos.
Devastating as the recent stock market decline is – particularly after two straight years of 20%+ returns – a real downturn in the financial markets feels a whole lot worse, says our Director of High Yield Marty Fridson. The late 1970s/early 1980s was a bond market apocalypse, he says.